JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on DBV Technologies SA – American (DBVT – Research Report) today and set a price target of $5.00. The company’s shares closed last Monday at $2.51.
According to TipRanks.com, Wolleben has 0 stars on 0-5 stars ranking scale with an average return of -9.6% and a 35.1% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Madrigal Pharmaceuticals, and Clearside Biomedical.
Currently, the analyst consensus on DBV Technologies SA – American is a Moderate Buy with an average price target of $5.50.
The company has a one-year high of $5.99 and a one-year low of $1.15. Currently, DBV Technologies SA – American has an average volume of 778.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Read More on DBVT:
- Check Point Reports Solid Q2 Results; Stock Price Drops 4.5%
- Rosenblatt Securities Reiterates a Buy Rating on Harmonic (HLIT)
- Coherus BioSciences Announces New Employment Inducement Grants
- ValOre’s Second Core Rig Commences Drilling, with First Drill Intercepting Multiple Zones of Shallow Radioactivity at Dipole Uranium Target, Angilak Property
- ASML Stock: Unmatched Moat and Strong Momentum to Drive Returns